UNSPSC 51393102: Guanabenz

This classification denotes an alpha-adrenergic agonist with the molecular formula C8H8Cl2N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GGD30112WC, chemically known as (2,6-dichlorophenyl)methylideneaminoiminomethanediamine but generally known as guanabenz, which bears US NIH Compound Identifier 3517. European Medicines Agency schedules Guanabenz in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07978MIG.

GUANABENZ is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guanabenz under HS 29280090 and SITC 51486. As of Q4 2014, GUANABENZ remains the US FDA Preferred Term for this commodity. Guanabenz bears US NLM identifiers UMLS ID C0018312 and NCI Concept Code C83740. SMILES: Clc1c(c(Cl)ccc1)/C=N/N=C(/N)N.

UNSPSC 51393102 Guanabenz is a Commodity code that covers pharmaceutical products, but the recent state and local opportunities tagged under it reflect broader pharmaceutical procurement activity centered on emergency response and pharmacy benefit management rather than guanabenz specifically. Seminole County, Florida's June 2026 IFB for naloxone and drug deactivation systems and the Texas Health and Human Services Commission's April 2026 RFI on direct-to-manufacturer prescription programs illustrate the actual scope of work moving through procurement channels under this code: acquisition of pharmaceutical supplies and services for public health, emergency response, and managed pharmacy programs. State and local buyers under this code include county health departments, state health and human services agencies, and public health authorities. The work spans both routine pharmaceutical supply contracts with fixed-fee pricing and preliminary market-research phases to establish new purchasing relationships with manufacturers and pharmacy benefit intermediaries.

Recent activity concentrates in Florida and Texas. Seminole County's naloxone procurement is structured as a competitive IFB with annual volumes (1,900 units of naloxone and 800 drug deactivation systems annually), quarterly delivery requirements to a designated county health facility, and a two-year initial term with a one-year renewal option; bids were due July 26, 2023. Texas HHS's RFI, posted April 3, 2026, represents an earlier-stage information-gathering phase focused on vendor capabilities for direct manufacturer contracting outside traditional pharmacy benefit manager relationships, with no formal award or budget identified at the RFI stage. The Seminole County opportunity requires electronic bid submission through the county e-Procurement Portal, compliance with drug-free workplace certification and E-Verify, and standard insurance coverage (workers' compensation, commercial general liability, professional liability). Neither opportunity specifies set-aside designations for disadvantaged enterprises.